ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
30 April 2024 - 9:00PM
ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company
focused on the generation and development of antibody therapeutics
targeting toxic misfolded proteins in neurodegenerative diseases
such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis
(ALS) and multiple system atrophy (MSA), today announced the
publication of a paper titled, “Relationship between therapeutic
activity and preferential targeting of toxic soluble aggregates by
amyloid-beta-directed antibodies," in the online journal, bioRxiv.
The study characterized and compared the binding profile of
various amyloid-beta (Ab)-directed antibodies to monomers, soluble
oligomers and insoluble Ab fibrils. The results indicate that
selectivity for soluble toxic Aß oligomers may be a driver of
clinical efficacy and indicated that PMN310 displayed the greatest
degree of oligomer selectivity. PMN310, the Company’s novel
monoclonal antibody being evaluated as a treatment for Alzheimer’s
disease (AD), is currently undergoing Phase 1a clinical studies in
healthy volunteers, with initial safety and pharmacokinetic data
expected in mid-2024.
“The data in this publication highlight PMN310’s high degree of
selectivity for toxic Ab oligomers and its differentiation from
other Ab-directed antibodies,” stated Neil Warma, Chief Executive
Officer of ProMIS Neurosciences. “We believe that PMN310’s ability
to avoid both monomer and plaque binding has the potential to
improve efficacy and reduce the risk of amyloid-related imaging
abnormalities (ARIA), a key indicator of edema and microhemorrhage
risk associated with plaque binding antibody therapies currently on
the market and in development. We look forward to the top-line data
readout for our Phase 1a study in the coming months and to
advancing PMN310 into a Phase 1b multiple ascending dose study in
AD patients.”
Aß-directed antibodies tested clinically for therapeutic
activity against AD have shown varying degrees of efficacy. A
side-by-side comparison of antibody binding to different molecular
species of Aß conducted by ProMIS provided insight into the
observed variability in clinical outcomes. A correlation was
observed between reported clinical efficacy and the ability of an
antibody to retain binding to soluble oligomers from AD brains when
faced with monomer competition. PMN310 showed a high degree of
resistance to monomer competition. Importantly, unlike all other
antibodies tested, PMN310 also avoided binding to plaque and
vascular deposits of Ab. Consequently, PMN310, may reduce the risk
of brain edema (ARIA-E) and microhemorrhages (ARIA-H) often
associated with plaque-binding antibodies. This premise is
supported by the results showing that weekly dosing of a murine
version of PMN310 at very high doses (800 mg/kg) for 26 weeks in a
mouse model of AD did not cause any detectable brain hemorrhages
upon microscopic examination.
The complete article can be accessed online here.
About ProMIS Neurosciences
Inc.
ProMIS Neurosciences Inc. is a clinical stage biotechnology
company focused on generating and developing antibody therapeutics
selectively targeting toxic misfolded proteins in neurodegenerative
diseases such as Alzheimer’s disease (AD), amyotrophic lateral
sclerosis (ALS) and multiple system atrophy (MSA). The Company’s
proprietary target discovery engine applies a thermodynamic,
computational discovery platform - ProMIS™ and Collective
Coordinates - to predict novel targets known as Disease Specific
Epitopes on the molecular surface of misfolded proteins. Using this
unique approach, the Company is developing novel antibody
therapeutics for AD, ALS and MSA. ProMIS has offices in Cambridge,
Massachusetts and Toronto, Ontario.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Certain information in
this news release constitutes forward-looking statements and
forward-looking information (collectively, “forward-looking
information”) within the meaning of applicable securities laws. In
some cases, but not necessarily in all cases, forward-looking
information can be identified by the use of forward-looking
terminology such as “plans”, “excited to”, “targets”, “expects” or
“does not expect”, “is expected”, “an opportunity exists”, “is
positioned”, “estimates”, “intends”, “assumes”, “anticipates” or
“does not anticipate” or “believes”, or variations of such words
and phrases or state that certain actions, events or results
“may”, “could”, “would”, “might”, “will” or “will be taken”,
“occur” or “be achieved”. In addition, any statements that refer
to expectations, projections or other characterizations of future
events or circumstances contain forward-looking information.
Specifically, this news release contains forward-looking
information relating to the study and reported therapeutic activity
and preferential targeting of toxic soluble aggregates by
Aß-directed antibodies and the potential implications thereof, the
Company's expectations regarding its clinical development of its
lead product, PMN310, for AD, and the Company’s anticipated
top-line data readout for our Phase 1a study in the first half of
2024 and plans to advance into a Phase 1b multiple ascending dose
study in AD patients. Statements containing
forward-looking information are not historical facts but
instead represent management's current expectations, estimates and
projections regarding the future of our business, future plans,
strategies, projections, anticipated events and trends, the
economy and other future conditions. Forward-looking information is
necessarily based on a number of opinions, assumptions and
estimates that, while considered reasonable by the Company as of
the date of this news release, are subject to known and unknown
risks, uncertainties and assumptions and other factors that may
cause the actual results, level of activity, performance or
achievements to be materially different from those expressed or
implied by such forward-looking information, including, but not
limited to, the risk that the results of nonclinical studies and
early clinical trials are not necessarily predictive of future
results with PMN310, the Company’s ability to fund its operations
and continue as a going concern, its accumulated deficit and the
expectation for continued losses and future financial results.
Important factors that could cause actual results to differ
materially from those indicated in the forward-looking information
include, among others, the factors discussed throughout the “Risk
Factors” section of the Company's most recently filed Annual Report
on Form 10-K for the year ended December 31, 2023 and in its
subsequent filings filed with the United States Securities and
Exchange Commission. Except as required by applicable securities
laws, the Company undertakes no obligation to publicly update any
forward-looking information, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
For further information:
Visit us at www.promisneurosciences.com
Please submit media inquiries to
info@promisneurosciences.com.
For Investor Relations, please
contact: Stern Investor RelationsAnne Marie Fields,
Managing Directorannemarie.fields@sternir.comTel. 212-362-1200
ProMIS Neurosciences (TSX:PMN)
Historical Stock Chart
From Nov 2024 to Dec 2024
ProMIS Neurosciences (TSX:PMN)
Historical Stock Chart
From Dec 2023 to Dec 2024